The relationship between change in tumor size and survival in advanced NSCLC treated with gefitinib

19066 Background: Gefitinib is cytostatic agents. A lot of patients treated with this drug might have stable disease (SD) as their best response, rather than tumor regression. In this study, we retrospectively review the data of Chinese NSCLC patients who received a single agent of gefitinib (250mg/day) with the purpose of identifying the relationship between change in tumor size and survival in SD group patients. Methods: 139 NSCLC patients were collected retrospectively from a multi-center clinical trial in during November of 2003 to June of 2004. The relationship between change in tumor size during treatment and the time to progression (TTP) were analysis. The differences in TTP were compared by Kaplan-Meier method and log-rank test. Results: Median TTP of 139 NSCLC patients was 98 days. Median TTP of patients evaluated tumor response (CR+PR), SD, and progressive disease (PD) is 125 days, 91 days and 30 days respectively(P<0.01). 74 patients were evaluated as SD, In this SD group, 19 patients with any ...